Risk of second primary cancer following prostate cancer radiotherapy: DVH analysis using the competitive risk model

被引:25
|
作者
Takam, R. [1 ,2 ]
Bezak, E. [1 ,2 ]
Yeoh, E. E. [3 ,4 ]
机构
[1] Univ Adelaide, Sch Chem & Phys, Adelaide, SA, Australia
[2] Royal Adelaide Hosp, Dept Med Phys, Adelaide, SA 5000, Australia
[3] Univ Adelaide, Sch Med, Adelaide, SA, Australia
[4] Royal Adelaide Hosp, Dept Radiat Oncol, Adelaide, SA 5000, Australia
来源
PHYSICS IN MEDICINE AND BIOLOGY | 2009年 / 54卷 / 03期
关键词
DOSE-RATE BRACHYTHERAPY; MODULATED RADIATION-THERAPY; HDR BRACHYTHERAPY; MALIGNANCIES; MONOTHERAPY; CARCINOMA; INDUCTION; TOXICITY; BLADDER; MEN;
D O I
10.1088/0031-9155/54/3/009
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
This study aimed to estimate the risk of developing second primary cancer (SPC) corresponding to various radiation treatment techniques for prostate cancer. Estimation of SPC was done by analysing differential dose-volume histograms (DDVH) of normal tissues such as rectum, bladder and urethra with the competitive risk model. Differential DVHs were obtained from treatment planning systems for external beam radiotherapy (EBRT), low-dose-rate (LDR) and high-dose-rate (HDR) brachytherapy techniques. The average risk of developing SPC was no greater than 0.6% for all treatment techniques but was lower with either LDR or HDR brachytherapy alone compared with any EBRT technique. For LDR and HDR brachytherapy alone, the risk of SPC for the rectum was 2.0 x 10(-4)% and 8.3 x 10(-5)% respectively compared with 0.2% for EBRT using five-field 3D-CRT to a total dose of 74 Gy. Overall, the risk of developing SPC for urethra following all radiation treatment techniques was very low compared with the rectum and bladder. Treatment plans which deliver equivalent doses of around 3-5 Gy to normal tissues were associated with higher risks of development of SPC.
引用
收藏
页码:611 / 625
页数:15
相关论文
共 50 条
  • [1] Prostate Brachytherapy and Second Primary Cancer Risk: A Competitive Risk Analysis
    Hinnen, Karel A.
    Schaapveld, Michael
    van Vulpen, Marco
    Battermann, Jan. J.
    van der Poel, Henk
    van Oort, Inge M.
    van Roermund, Joep G. H.
    Monninkhof, Evelyn M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (34) : 4510 - 4515
  • [2] PROSTATE BRACHYTHERAPY INDUCED SECOND PRIMARY CANCER: A COMPETITIVE RISK ANALYSIS
    van Vulpen, M.
    Schaapveld, M.
    Hinnen, K.
    van der Poel, H.
    van Oort, I.
    Roermund, J.
    Battermann, J. J.
    Franken, S.
    van der Heide, U.
    Monninkhof, E.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2011, 99 : S387 - S387
  • [3] Risk of rectal second cancer following prostate radiotherapy
    Bezak, E.
    Takam, R.
    Yeoh, E.
    Marcu, L.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2007, 84 : S68 - S69
  • [4] Risk of second malignancies following radiotherapy for prostate cancer
    Hegemann, N. -S
    Ganswindt, U.
    Doerr, M.
    Hoerl, C.
    Molls, M.
    Hoelzel, D.
    Engel, J.
    Belka, C.
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2015, 191 : S10 - S10
  • [5] Risk of second cancer following radiotherapy for prostate cancer: a population-based analysis
    Nina-Sophie Hegemann
    Anne Schlesinger-Raab
    Ute Ganswindt
    Claudia Hörl
    Stephanie E. Combs
    Dieter Hölzel
    Jürgen E. Gschwend
    Christian Stief
    Claus Belka
    Jutta Engel
    [J]. Radiation Oncology, 12
  • [6] Risk of second cancer following radiotherapy for prostate cancer: a population-based analysis
    Hegemann, Nina-Sophie
    Schlesinger-Raab, Anne
    Ganswindt, Ute
    Horl, Claudia
    Combs, Stephanie E.
    Holzel, Dieter
    Gschwend, Jurgen E.
    Stief, Christian
    Belka, Claus
    Engel, Jutta
    [J]. RADIATION ONCOLOGY, 2017, 12
  • [7] Risk of second primary malignancies associated with radiotherapy in prostate cancer patients: competing risk analysis
    Wu, Yijun
    Li, Yunlong
    Han, Chang
    Chong, Yuming
    Kang, Kai
    Liu, Zhikai
    Zhang, Fuquan
    [J]. FUTURE ONCOLOGY, 2022, 18 (04) : 445 - 455
  • [8] Risk of second primary cancers after radiotherapy for prostate cancer
    Hegemann, N. S.
    Ganswindt, U.
    Engel, J.
    Belka, C.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S158 - S158
  • [9] Risk of second cancer following radiotherapy
    Toma-Dasu, Iuliana
    Wojcik, Andrzej
    Lindblom, Emely Kjellsson
    [J]. PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS, 2017, 42 : 211 - 212
  • [10] Second malignancy risk in prostate cancer and radiotherapy
    Charas, Tomer
    Taggar, Amandeep
    Zelefsky, Michael J.
    [J]. FUTURE ONCOLOGY, 2017, 13 (05) : 385 - 389